Value of serum neurofilament light chain levels as a biomarker of suboptimal treatment response in MS clinical practice

被引：0

作者：

Yaldizli, O. ^{[1
,2
]}

Benkert, P. ^{[3
]}

Maceski, A. ^{[1
,2
]}

Barakovic, M. ^{[2
]}

Todea, R. -A. ^{[1
,2
]}

Cagol, A. ^{[1
,2
]}

Schaedelin, S. ^{[1
]}

Disanto, G. ^{[4
]}

Oechtering, J. ^{[1
,2
]}

Orleth, A. ^{[1
,2
]}

Rey, D. ^{[1
,2
]}

Sinnecker, T. ^{[1
,2
]}

Rahmanzadeh, R. ^{[1
,2
]}

Zadic, S. ^{[1
,2
]}

Galbusera, R. ^{[1
,2
]}

Achtnichts, L. ^{[5
]}

Aeschbacher, S. ^{[1
]}

Chan, A. ^{[6
,7
]}

Conen, D. ^{[1
]}

Derfuss, T. ^{[1
,2
]}

Findling, O. ^{[5
]}

Fischer-Barnicol, B. ^{[1
,2
]}

Hrusovsky, K. ^{[8
]}

Kropshofer, H. ^{[9
]}

Lalive, P. ^{[10
]}

Lieb, J. ^{[1
]}

Lorscheider, J. ^{[1
,2
]}

Maggi, P. ^{[11
,12
]}

Mueller, C. ^{[1
]}

Mueller, S. ^{[13
]}

Naegelin, Y. ^{[1
,2
]}

Mueller, J. ^{[1
,2
]}

Oksenberg, J. ^{[14
]}

Pot, C. ^{[15
]}

Du Pasquier, R. ^{[15
]}

Radue, E. -W. ^{[1
,2
]}

Salmen, A. ^{[6
,7
]}

Vehoff, J. ^{[13
]}

Waubant, E. ^{[14
]}

Wellmann, S. ^{[16
]}

Wiendl, H. ^{[17
]}

Wuerfel, J. ^{[18
]}

Zecca, C. ^{[4
]}

Berger, K. ^{[17
]}

Gobbi, C. ^{[4
]}

Kappos, L. ^{[2
,19
]}

Leppert, D. ^{[1
,2
]}

Granziera, C. ^{[1
,2
]}

Kuhle, J. ^{[1
,2
]}

机构：

[1] Univ Hosp Basel, Basel, Switzerland

[2] Univ Basel, Basel, Switzerland

[3] Univ Basel, Univ Hosp Basel, Basel, Switzerland

[4] Reg Hosp Southern Switzerland EOC, Lugano, Switzerland

[5] Cantonal Hosp Aarau, Aarau, Switzerland

[6] Univ Hosp, Inselspital Bern, Bern, Switzerland

[7] Univ Bern, Bern, Switzerland

[8] Quanterix, Billerica, MA USA

[9] Novartis Pharma AG, Basel, Switzerland

[10] Geneva Univ Hosp, Geneva, Switzerland

[11] Lausanne Univ Hosp, Lausanne, Switzerland

[12] Univ Lausanne, Lausanne, Switzerland

[13] Cantonal Hosp St Gallen, St Gallen, Switzerland

[14] Univ Calif San Francisco, San Francisco, CA 94143 USA

[15] Univ Hosp Lausanne, Lausanne, Switzerland

[16] Univ Regensburg, Univ Childrens Hosp Regensburg KUNO, Regensburg, Germany

[17] Univ Munster, Munster, Germany

[18] Med Image Anal Ctr, Basel, Switzerland

[19] Univ Hosp, Basel, Switzerland

来源：

MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

PS09.05

引用

页码：26 / 27

页数：2

共 50 条

[31] Serum neurofilament light chain correlates with disease activity and predicts clinical and MRI outcomes in MS
Barro, C.
Benkert, P.
Grobke, S.
Naegelin, Y.
Disanto, G.
Amann, M.
Magon, S.
Derfuss, T.
Yaldizli, O.
Parmar, K.
Wuerfel, J.
Kappos, L.
Kuhle, J.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 297 - 298
[32] Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
Rosenstein, Igal
Axelsson, Markus
Novakova, Lenka
Blennow, Kaj
Zetterberg, Henrik
Lycke, Jan
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (06) : 872 - 884
[33] CSF Neurofilament Light Chain Levels as a Biomarker for Pediatric Demyelinating Diseases
Mar, Soe
Piccio, Laura
NEUROLOGY, 2016, 86
[34] Increased Serum Neurofilament Light Chain Levels in Spinocerebellar Ataxia
Shin, Hye-Rim
Moon, Jangsup
Lee, Woo-Jin
Lee, Han Sang
Kim, Eun Young
Lee, Soon-Tae
Jung, Keun-Hwa
Park, Kyung-Il
Jung, Ki-Young
Kim, Manho
Lee, Sang Kun
Chu, Kon
ANNALS OF NEUROLOGY, 2020, 88 : S172 - S172
[35] Increased levels of neurofilament light chain in suicide attempters' serum
Ramezani, Mahtab
Simani, Leila
Fard, Mahdiye Golestani
Abbaszadeh, Fatemeh
Shadnia, Shahin
TRANSLATIONAL NEUROSCIENCE, 2022, 13 (01) : 218 - 223
[36] Epstein-Barr Virus infection and serum neurofilament light chain levels before MS onset
Bjornevik, K.
Cortese, M.
Healy, B. C.
Leppert, D.
Niebuhr, D. W.
Scher, A. I.
Kuhle, J.
Munger, K. L.
Ascherio, A.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 368 - 369
[37] Evobrutinib reduces relapses and MRI outcomes in MS: association with baseline serum neurofilament light chain levels
Kuhle, J.
Kappos, L.
Montalban, X.
Li, Y.
Thangavelu, K.
Hyvert, Y.
Tomic, D.
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 290 - 291
[38] Serum neurofilament light chain levels are increased at the onset of PML in natalizumab-treated MS patients
Dalla Costa, G.
Martinelli, V.
Moiola, L.
Sangalli, F.
Colombo, B.
Finardi, A.
Cinque, P.
Kolb, E. -M.
Haghikia, A.
Gold, R.
Furlan, R.
Comi, G.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 327 - 327
[39] Serum neurofilament light as a biomarker of disability and neurodegeneration in MS patients of the same age
Loonstra, F. C.
De Ruijter, L. R. J.
Schoonheim, M. M.
Strijbis, E. M.
Moraal, B.
Bijvank, J. A. Nij
Petzold, A.
Uitdehaag, B. M. J.
Teunissen, C. E.
Killestein, J.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 509 - 510
[40] Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations
Ziemssen, Tjalf
Akgun, Katja
Czlonkowska, Anna
Antos, Agnieszka
Bembenek, Jan
Kurkowska-Jastrzebska, Iwona
Przybylkowski, Adam
Skowronska, Marta
Smolinski, Lukasz
Litwin, Tomasz
MOVEMENT DISORDERS, 2022, 37 (05) : 1074 - 1079

← 1 2 3 4 5 →